Plural Nitrogens Nonionically Bonded Patents (Class 514/564)
-
Publication number: 20090028937Abstract: The present invention has an object to provide a tablet capable of comprising ornithine hydrochloride in a higher content; and a process for producing the same, and provides the tablet comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin; and the process for producing a tablet comprising ornithine hydrochloride, which comprises compression molding a mixture comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin by a direct tableting method.Type: ApplicationFiled: January 30, 2006Publication date: January 29, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Toshikazu Kamiya, Masao Kimura, Yasushi Sakai
-
Publication number: 20090030005Abstract: This invention is in the field of pharmaceutical agents and specifically relates to combinations, compositions, uses and methods for treating cancer.Type: ApplicationFiled: July 17, 2008Publication date: January 29, 2009Applicant: AMGEN INC.Inventors: Alexander Kamb, Astrid Ruefli-Brasse
-
Publication number: 20090005293Abstract: Provided are compositions comprising beta-alanylhistidine peptides and beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.Type: ApplicationFiled: August 29, 2008Publication date: January 1, 2009Inventors: Roger Harris, Mark Dunnett
-
Publication number: 20080317870Abstract: Disclosed are compositions and methods used to treat and/or prevent cancer and metabolic diseases, such as psoriasis. In one aspect, the present invention pertains to the use of cross-linking analogs of vitamin D and its metabolites employed for the treatment of prostate cancer.Type: ApplicationFiled: August 25, 2008Publication date: December 25, 2008Inventors: Rahul Ray, Narashima Swamy
-
Publication number: 20080319076Abstract: The invention relates to compositions (e.g., nutritional supplements) comprising, consisting essentially of, or consisting of a creatine bicarbonate, and to methods of making and using said compositions.Type: ApplicationFiled: September 2, 2008Publication date: December 25, 2008Inventor: Bruce Kneller
-
Publication number: 20080280984Abstract: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others.Type: ApplicationFiled: April 19, 2005Publication date: November 13, 2008Applicant: Strategic Science & Technologies, LLCInventor: Eric Thor Fossel
-
Publication number: 20080267862Abstract: Present invention provides a method for treating cancer which comprises co-administration of an angiogenic agent to enhance the vascular supply within tumors, particularly tumors capable of maintaining their viability under hypoxic conditions, and a anticancer therapy (e.g. chemotherapy and radiation therapy) to which the cancer is susceptible. Induction of angiogenesis increases the delivery of anticancer agents to the hypoxic tumor cells within the tumors, and as a result, improves the effectiveness of the anticancer therapy in eliminating or reducing cancers. The present invention also includes formulations comprising of lysine(L- and/or D-isomers as well as, or, their “activated” version either in isolation or in various combinations, as described, along with additive(s) and one or more chemotherapeutic agent(s) and/or radio-sensitizing agent(s).Type: ApplicationFiled: April 29, 2008Publication date: October 30, 2008Inventor: DEBATOSH DATTA
-
Publication number: 20080260708Abstract: Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself.Type: ApplicationFiled: April 19, 2007Publication date: October 23, 2008Inventor: Mickey A. Hall
-
Publication number: 20080255234Abstract: Use of lysine imines and compositions containing them as a source of rumen protected lysine for ruminant animals.Type: ApplicationFiled: April 11, 2007Publication date: October 16, 2008Applicant: ZINPRO CORPORATIONInventors: PETER A. STARK, MAHMOUD ABDEL-MONEM
-
Publication number: 20080241165Abstract: The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-? structures and the biological role of these cross-? structures. In one embodiment, the invention discloses a method for modulating extracellular protein degradation and/or protein clearance comprising modulating cross-?(beta) structure formation (and/or cross-? structure-mediated activity) of the protein present in the circulation.Type: ApplicationFiled: October 31, 2007Publication date: October 2, 2008Applicant: Crossbeta Biosciences B.V.Inventors: Louise Maria Johanna Kroon-Batenburg, Barend Bouma, Onno Wouter Kranenburg, Martijn Frans Ben Gerard Gebbink Bunnik
-
Publication number: 20080234379Abstract: Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.Type: ApplicationFiled: May 16, 2008Publication date: September 25, 2008Inventors: Marshall L. Summar, Brian W. Christman, Frederick E. Barr
-
Publication number: 20080233208Abstract: This invention relates to a use of the compound of formula (I), Erianin, in preparing pharmaceutical for treating tumorsType: ApplicationFiled: January 31, 2008Publication date: September 25, 2008Applicant: The Jiang Cell Biomedical Research Co., Ltd.Inventors: Yiping Li, Ning Li, Danping Zhou, Lizuan Chen
-
Publication number: 20080213403Abstract: The present invention provides a method for treating a pulmonary disease state in mammals by protecting indigenous in vivo levels of nitric oxide in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of a nitric oxide mediator, wherein the nitric oxide mediator is selected from the group consisting of ?-keto acids having four or more carbon atoms, precursors of ?-keto acids having four or more carbon atoms, and the salts thereof.Type: ApplicationFiled: January 22, 2008Publication date: September 4, 2008Inventor: Alain Martin
-
Patent number: 7420002Abstract: Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed.Type: GrantFiled: June 11, 2002Date of Patent: September 2, 2008Assignee: XenoportInventors: Mark Gallop, Kenneth C. Cundy, Randall A. Scheuerman, Ronald W. Barrett, Noa Zerangue
-
Publication number: 20080206290Abstract: A cosmetic combination product, wherein the product comprises at least two components selected from (a) one or more dietary supplements, (b) one or more cosmetic preparations for topical application to human skin, and (c) one or more patches for adhesion to human skin. Each of the selected components (a) to (c) comprises at least one cosmetically active substance which is also comprised in the other selected component(s). This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.Type: ApplicationFiled: August 15, 2007Publication date: August 28, 2008Applicant: BEIERSDORF AGInventors: Jens SCHULZ, Rainer Kroepke, Andreas Schepky, Julia Eckert, Urte Koop, Sabine Faenger
-
Publication number: 20080206222Abstract: A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.Type: ApplicationFiled: August 5, 2005Publication date: August 28, 2008Inventors: Nobuhiko Miwa, Shinobu Ito, Kenji Matsubayashi
-
Patent number: 7416740Abstract: Hydrochloric acid, sulfuric acid or an L-lysine solution having an equivalent ratio of anion/L-lysine higher than 0.95 is added to a raw material L-lysine solution having an equivalent ratio of anion/L-lysine lower than 0.68 to adjust the equivalent ratio of anion/L-lysine of the raw material solution to be in the range of 0.68 to 0.95, and the obtained L-lysine solution or a concentrate thereof is granulated and dried to obtain a dry granulated product having a high L-lysine content and showing low caking property and low hygroscopic property.Type: GrantFiled: January 24, 2003Date of Patent: August 26, 2008Assignee: Ajinomoto Co., Inc.Inventors: Takeshi Kushiki, Junko Morikawa, Kazuhiko Hasegawa
-
Patent number: 7414077Abstract: Methods are provided for promoting longevity and decreasing the incidence of ageing associated pathologies (e.g. cancer) by the administration of one or more of the following LFFA: linoleic, oleic, and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and CoA LFFA formulations are described which protect the organism from acute physical stress, tissue damage, and hypoxia, either due to trauma or secondary to surgical procedures.Type: GrantFiled: April 12, 2002Date of Patent: August 19, 2008Inventor: Marco Chacon
-
Publication number: 20080194665Abstract: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided, in particular methionine, phenylalanine, histidine, tryphtophan, as well as non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e., cystine and cysteine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.Type: ApplicationFiled: April 17, 2008Publication date: August 14, 2008Inventors: Franco CONTI, Francesco Saverio Dioguardi
-
Publication number: 20080194467Abstract: Improved methods for treating cancer which employ combinations comprising cadherin antagonists with certain anticancer agents or treatments are provided. The methods of the invention involve the administration of cadherin antagonist before, concurrent with, or after, administration of an anticancer agent or treatment and provide unexpectedly improved therapeutic benefit in the treatment of tumors growing in vivo.Type: ApplicationFiled: September 27, 2007Publication date: August 14, 2008Applicants: ADHEREX TECHNOLOGIES, INC., DEPARTMENT OF VETERANS AFFAIRSInventors: William Paul Peters, Brian Huber, Douglas Scott Tyler
-
Publication number: 20080182811Abstract: Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine and hydroxyproline are used as a group II metabotropic glutamate receptor activator; and cysteine is used as a group III metabotropic glutamate receptor activator.Type: ApplicationFiled: December 21, 2007Publication date: July 31, 2008Applicant: Ajinomoto Co., Inc.Inventors: Takeaki Ohsu, Sen Takeshita, Mitsuo Takahashi, Yuzuru Eto
-
Publication number: 20080153889Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds.Type: ApplicationFiled: February 29, 2008Publication date: June 26, 2008Inventors: John D. Imig, John R. Falck
-
Publication number: 20080145458Abstract: Pharmaceutical compositions containing: extracts of Tribulus terrestris, Epimedium koreanum, Cinnamon cassia in the weight ratio of 1.5-3.5:1-2:0.1-0.4 respectively; and optionally arginine or a physiologically equivalent ester, salt or precursor thereof. The compositions are useful in the treatment of male and female sexual dysfunctions. A method of treatment using the pharmaceutical compositions is also described.Type: ApplicationFiled: February 25, 2008Publication date: June 19, 2008Applicant: INDENA S.p.AInventors: Ezio BOMBARDELLI, Paolo MORAZZONI, Antonella RIVA, Roberto SEGHIZZI
-
Patent number: 7384979Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.Type: GrantFiled: May 30, 2006Date of Patent: June 10, 2008Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Peter J. Connolly, William V. Murray, Steven K. Wetter, Sigmond Johnson, Victor T. Bandurco, Jacqueline Bussolari
-
Publication number: 20080119554Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.Type: ApplicationFiled: November 28, 2005Publication date: May 22, 2008Inventors: Rajiv Jalan, Kamal Nayan Jalan
-
Publication number: 20080119421Abstract: A process for treating a biological organism, comprising the steps in which a cell cycle arresting drug is administered to the organism to produce synchronized cells, the microtubules within the synchronized cells are stabilized by means of a microtubule stabilizing agent, and the synchronized cells with the stabilized microtubules are then contacted with mechanical vibrational energy.Type: ApplicationFiled: October 28, 2004Publication date: May 22, 2008Inventors: Jack Tuszynski, Howard J. Greenwald, Stephen H. Curry, Kendrick Goss
-
Patent number: 7374770Abstract: Polyethylene glycol ethers of alkyl alcohols having the general formula CH3(CH2)xCH2(OCH2CH2)nOH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.Type: GrantFiled: August 13, 2002Date of Patent: May 20, 2008Assignee: SkinMedica, Inc.Inventors: Joyce T. Chou, Prakash Parab
-
Publication number: 20080076796Abstract: Use is disclosed of (a) an AlDH-inhibitory amount of a Trp metabolite, or an analogue or derivative thereof or (b) a bioprecursor thereof, or (c) a potentiator of (a) and/or (b), in the preparation of a medicament for treating alcoholism and/or alcohol dependence.Type: ApplicationFiled: July 2, 2001Publication date: March 27, 2008Inventor: Abdulla Abu-Bakr Badawy
-
Publication number: 20080057136Abstract: The invention relates to antimicrobial compositions that can be used for disinfecting and can be applied in various aspects of the national economy, medicine, and laboratories of all types. The antimicrobial compositions comprise a chelating metal complex compound with a monodentate bidentate or polydentate ligand that exhibits affinity to hydrogen ion, an ionogenic surfactant, and a solvent. The compositions of the invention display antiseptic properties. The antimicrobial compositions are active against Gram-positive and Gram-negative bacteria, fungi, viruses, and spores, and can be applied in a broad temperature interval. Methods of using the compositions of the present invention in the treatment and prevention of diseases caused by a variety of pathogens are further provided.Type: ApplicationFiled: November 11, 2004Publication date: March 6, 2008Applicant: Veckis Industries Ltd.Inventors: Victor S. Polyakov, Valeriy V. Ermilov, Vladimir S. Kuzmin, Oleg I. Lukashov
-
Publication number: 20080033040Abstract: The present invention concerns screening methods and compositions relating to endothelial cell function. More specifically, it provides screening methods to identify or characterize pathways and factors involved in endothelial cell function by employing conditions that simulate physiological stress. Additional methods can be implemented to identify candidate drugs for the treatment of endothelial cell dysfunction, such as cardiovascular disease or diabetes.Type: ApplicationFiled: March 9, 2005Publication date: February 7, 2008Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATINInventors: Khalid Kader, Christian H. Coyle
-
Patent number: 7323452Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: December 20, 2004Date of Patent: January 29, 2008Assignee: Wardan, L.L.C.Inventors: Ward B. Bowen, Jr., Daniel S. Daniel
-
Patent number: 7320988Abstract: This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALEs) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs.Type: GrantFiled: October 27, 2004Date of Patent: January 22, 2008Assignee: City of HopeInventors: Samuel Rahbar, James L. Figarola
-
Patent number: 7318930Abstract: A composition which causes adult boring bark beetles to discontinue boring, discontinue laying eggs and become disoriented and bore out of the tree or cease boring altogether and die is described. Additional tests have shown that beetles will not infest a tree which has been treated with the composition. Furthermore, the composition also causes beetle larvae to cease boring and die and also causes egg sacks to shrivel and die.Type: GrantFiled: November 6, 2002Date of Patent: January 15, 2008Inventor: William Steed
-
Publication number: 20070286909Abstract: Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanine, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histidine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia.Type: ApplicationFiled: June 7, 2007Publication date: December 13, 2007Inventors: Daniel S. Smith, Timothy Kuss, Julia Ross
-
Patent number: 7273888Abstract: The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the ODC inhibitor difuoromethylornithine (DFMO) is disclosed as a useful pharmacological agent in the modulation and treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.Type: GrantFiled: November 1, 2002Date of Patent: September 25, 2007Assignee: ALS Therapy Development Foundation, Inc.Inventors: Tennore Ramesh, Sean Scott
-
Patent number: 7261878Abstract: A topical composition useful for reducing in hair growth includes ?-difluoromethylornithine and a dermatologically acceptable vehicle comprising at least 4% by weight of a polyoxyethylene ether having the chemical formula R(OCH2 CH2)bOH, where R is a saturated or unsaturated alkyl group including from 6 to 22 carbon atoms and b is from 2 to 200.Type: GrantFiled: July 17, 2002Date of Patent: August 28, 2007Assignee: The Gillette CompanyInventors: Peter Styczynski, Gurpreet S. Ahluwalia, Douglas Shander
-
Patent number: 7244749Abstract: The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.Type: GrantFiled: January 26, 2004Date of Patent: July 17, 2007Inventor: Matthias Rath
-
Patent number: 7235542Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 26, 2006Date of Patent: June 26, 2007Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 7157497Abstract: A method of stimulating or enhancing an ornithine-urea cycle in ruminant gut tissues, which entails either feeding to a ruminant an effective amount of a ruminant feed or feed supplement containing an effective amount of a compound which stimulates activity of one or more enzymes required in the ornithine-urea cycle.Type: GrantFiled: June 4, 2004Date of Patent: January 2, 2007Inventor: Brian James Bequette
-
Patent number: 7129273Abstract: This invention relates to a novel compound, dicreatine malate, comprising approximately two moles of creatine cations per one mole of malate anion. The creatine salt of this invention has been found to increase the bioavailability of both the creatine and malic acid moieties over and above the individual bioavailabilities of creatine monohydrate and malic acid base. Dicreatine malate vastly improves the production of Adenosine TriPhosphate (ATP) beyond the level of creatine monohydrate or any other creatine derivative. It also has a much greater efficacy in uses such as increasing muscle mass, increasing cell volumization, decreasing adipose stores, and for increasing overall strength and endurance.Type: GrantFiled: April 30, 2003Date of Patent: October 31, 2006Assignee: Creative Compounds, LLCInventors: Derek Wayne Cornelius, Gary Lee Haynes
-
Patent number: 7101911Abstract: Compounds of the formula I, in which M, A1, A2, K1 and K2 have the meanings given in the description are novel effective tryptase inhibitors.Type: GrantFiled: February 16, 2002Date of Patent: September 5, 2006Assignee: Altana Pharma AGInventor: Thomas Martin
-
Patent number: 7087644Abstract: The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, pharmaceutical compositions containing them, and methods for using them for treatment of cardiovascular disorders are also disclosed and claimed.Type: GrantFiled: August 31, 2000Date of Patent: August 8, 2006Assignee: Bayer AktiengesellschaftInventors: Cristina Alonso-Alija, Markus Heil, Dietmar Flubacher, Paul Naab, Josef Pernerstorfer, Johannes-Peter Stasch, Frank Wunder, Klaus Dembowsky, Elisabeth Perzborn, Elke Stahl
-
Patent number: 7048918Abstract: Disclosed are insect baits for attracting insects such as ants, flies and cockroaches. The baits include amino acids and a sugar. The baits can be combined with an insect toxicant to effectively control and eliminate insect populations. Methods for controlling insects using an insect bait of the invention are also disclosed.Type: GrantFiled: August 6, 2003Date of Patent: May 23, 2006Assignee: University of Florida Research Foundation, Inc.Inventors: Jack Richard Warner, Rudolf H. Scheffrahn
-
Patent number: 7045532Abstract: ACE-2 inhibitors for the treatment of body weight and related disorders are disclosed. ACE-2 inhibitors include peptides and small molecules. Examples of small molecule ACE-2 inhibitors include compounds of formula (I): Z-???(I) Wherein Z is a zinc coordinating moiety and ? is an amino-acid mimicking moiety, and pharmaceutically acceptabale salts thereof. Methods of using the inhibitors and pharmaceutical compositions containing the inhibitors to treat a body weight disorder, to decrease appetite, to increase muscle mass, to decrease body fat, to treat diabetes and to treat a state associated with altered lipid metabolism, are also described.Type: GrantFiled: October 31, 2001Date of Patent: May 16, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Susan L. Acton, Timothy D. Ocain, Alexandra E. Gould, Natalie A. Dales, Bing Guan, James A. Brown, Michael Patane, Vivek J. Kadambi, Michael Solomon, Alain Stricker-Krongrad
-
Patent number: 7045550Abstract: Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.Type: GrantFiled: August 7, 2002Date of Patent: May 16, 2006Assignee: Wisconsin Alumni Research FoundationInventors: William E. Fahl, John Kink
-
Patent number: 7005450Abstract: The present invention relates to 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.Type: GrantFiled: April 7, 2004Date of Patent: February 28, 2006Assignee: Pharmacia CorporationInventors: Richard C. Durley, James Sikorski, Donald W. Hansen, Jr., Michelle A. Promo, Ronald Keith Webber, Barnett S. Pitzele, Alok K. Awasthi, Alan Moormann
-
Patent number: 6998396Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 8, 2004Date of Patent: February 14, 2006Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 6995152Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 8, 2004Date of Patent: February 7, 2006Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 6987129Abstract: The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, ?-adrenergic receptor antagonists, ?-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g.Type: GrantFiled: March 6, 2002Date of Patent: January 17, 2006Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Vivien H. W. Mak, Stephen Grayson
-
Patent number: 6984661Abstract: The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C1-C8 alkyl substituted C1-C8 alkyl, aryl-C0-4-alkyl, substituted aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, substituted heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and substituted C3-C6 cycloalkylaryl-C0-2-alkyl; (b) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; (c) Y is C, O, S, NH or a single bond; and (d) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, (CH2)n COOR19 and substituted (CH2)n COOR19.Type: GrantFiled: January 21, 2003Date of Patent: January 10, 2006Assignee: Eli Lilly and CompanyInventors: James Robert Henry, YiHong Li